[Activators and inhibitors of fibrinolysis in chronic glomerulonephritis and amyloidosis].
Functional activities of plasminogen activators (FPAA) and their inhibitors and plasminogen activators's (PA), antigen level were determined in 31 patients with chronic glomerulonephritis, 23 patients with amyloidosis and 15 healthy persons. High FPAA correlated with favourable prognosis of diseases, elevated PA antigen level and diminished alpha 1-antitrypsin, alpha 2-macroglobulin and antiactivator activities. There were decreased PA antigen level and increased inhibitor's activities in group with zero FPAA. Protein loaded functional probe demonstrated the presence of PA reserves in high FPAA patients and "pathological proteolysis" in zero FPAA patients. The last phenomenon was likely connected to nonspecific proteases differed from PA.
Podorol'skaia
L V
LV
Andreenko
G V
GV
Poliantseva
L R
LR
Bumblite
I D
ID
D000686:Amyloidosis / Q000097:blood / Q000188:drug therapy*; D002908:Chronic Disease; D005342:Fibrinolysis / Q000187:drug effects*; D005921:Glomerulonephritis / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D010960:Plasminogen Activators / Q000494:pharmacology / Q000627:therapeutic use*; D015849:Plasminogen Inactivators / Q000494:pharmacology / Q000627:therapeutic use*; D011379:Prognosis; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use
D015849:Plasminogen Inactivators; D015842:Serine Proteinase Inhibitors; D010960:Plasminogen Activators
Aktivatory i ingibitory fibrinoliza pri khonicheskom glomerulonefrite i amiloidoze.